Eligard Observational Registry for Patients With Prostate Cancer
This trial is active, not recruiting.
|Condition||cancer of the prostate|
|Start date||September 2009|
|Trial size||330 participants|
|Trial identifier||NCT00992251, LEUPR_L_04620|
The objective of this registry is to collect data on patient demographics, medical history, change in prostate, bone and overall health of the patients receiving androgen ablation treatment using Eligard. Data collected through this national registry program provides an opportunity to increase knowledge of efficacy and safety of the long term treatment with Eligard, provide a platform to better identify patient segments for the therapy with Eligard®. Furthermore registries are the only tools to accurately capture rare adverse events.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Abbotsford, Canada||Dr. George Vrabec||no longer recruiting|
|Kelowna, Canada||Southern Interior Medical Research Corporation||no longer recruiting|
|Surrey, Canada||Dr. Cal Andreou||no longer recruiting|
|Surrey, Canada||Dr. Herman Kwan||no longer recruiting|
|Surrey, Canada||Dr. Nazif Omar||no longer recruiting|
|Barrie, Canada||Dr. Joseph Zadra||no longer recruiting|
|Brampton, Canada||Dr. Jonathan Giddens||no longer recruiting|
|Brantford, Canada||Brantford Urology Research, Medical Arts Building||no longer recruiting|
|Burlington, Canada||G. Kenneth Jansz Medicine Professional Corporation||no longer recruiting|
|Guelph, Canada||Dr. Eric Hirshberg||no longer recruiting|
|Hamilton, Canada||Dr. Anil Dapoor||no longer recruiting|
|Markham, Canada||Dr. Giovanni A. DiCostanzo||no longer recruiting|
|Newmarket, Canada||Dr. Morrie Liquornik||no longer recruiting|
|North York, Canada||Dr. Jack Barkin||no longer recruiting|
|North York, Canada||Dr. Roger Buckley||no longer recruiting|
|North York, Canada||Dr. Stanley Flax||no longer recruiting|
|Oakville, Canada||Dr. Richard Casey||no longer recruiting|
|Orillia, Canada||Orillia Urology Associates||no longer recruiting|
|Peterborough, Canada||Dr. Mohamed Elharram||no longer recruiting|
|Peterborough, Canada||Kawartha Urology Associates||no longer recruiting|
|Richmond Hill, Canada||Dr. Emmanuel Abara||no longer recruiting|
|Sault Ste. Marie, Canada||Dr. Vinod Mathur||no longer recruiting|
|Scarborough, Canada||Dr. Edward Woods||no longer recruiting|
|Sudbury, Canada||Dr. Bisshwajit Bora||no longer recruiting|
|Toronto, Canada||Dr. Jain Umesh||no longer recruiting|
|Toronto, Canada||Dr. Harold Kwok||no longer recruiting|
|Toronto, Canada||Dr. Nick Logarakis||no longer recruiting|
|Toronto, Canada||Dr. Ashis Chawla||no longer recruiting|
|Chicoutimi, Canada||Dr. Louis-Rene Barrette||no longer recruiting|
|Greenfield Park, Canada||Dr. Mahmoud Nachabe||no longer recruiting|
|Laval, Canada||Polyclinique Med Concorde||no longer recruiting|
|Montreal, Canada||Dr. Pierre Karakiewicz||no longer recruiting|
|Montreal, Canada||Dr. Thu Van Nguyen||no longer recruiting|
|Rimouski, Canada||Dr. John Vary||no longer recruiting|
|Val-d'Or, Canada||Dr. Thierry Tremblay||no longer recruiting|
|Westmount, Canada||Westmount Med Bldg||no longer recruiting|
Determine the percentage of patients that will achieve a hormone refractory status at 3 years after initiation of Androgen Deprivation Treatment with Eligard®.
time frame: 3 Years
Determine what baseline patient characteristics are associated with becoming hormone refractory at 3 years.
time frame: 3 years
Collect data on patient demographics, medical history, and change in prostate-, bone- and overall health of the patients receiving androgen ablation treatment using Eligard®.
time frame: 3 years
Collect referral data if the patient was referred to a medical oncologist during treatment.
time frame: 3 years
Male participants at least 18 years old.
Inclusion Criteria: - Patients > 18 years of age. - Histologically confirmed diagnosis of locally Advanced or Metastatic Prostate Cancer. - Patient starting an androgen deprivation therapy with Eligard at 3 or 4 month treatment frequency per standard of care. - Signed written informed consent. Exclusion Criteria: - Prior ADT (within 6 months). - Any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol. - Life expectancy less than 2 years.
|Official title||A Prospective, Single Product, Observational Registry Involving Patients Presenting With Locally Advanced or Metastatic Prostate Cancer Receiving Eligard as Androgen Deprivation Treatment.|
Call for more information